BPG is committed to discovery and dissemination of knowledge
Cited by in CrossRef
For: Ahmed F, Zakaria F, Enebong Nya G, Mouchli M. Sirolimus vs tacrolimus: Which one is the best therapeutic option for patients undergoing liver transplantation for hepatocellular carcinoma? World J Gastrointest Surg 2022; 14(8): 862-866 [PMID: 36157369 DOI: 10.4240/wjgs.v14.i8.862]
URL: https://www.wjgnet.com/1948-9366/full/v14/i8/862.htm
Number Citing Articles
1
Mohamed E. Nady, Ola M. Abd El-Raouf, El-Sayed M. El-Sayed. Linagliptin ameliorates tacrolimus-induced renal injury: role of Nrf2/HO-1 and HIF-1α/CTGF/PAI-1Molecular Biology Reports 2024; 51(1) doi: 10.1007/s11033-024-09533-2
2
Satoshi Asanuma, Koichiro Haruki, Kenei Furukawa, Shinji Onda, Yoshihiro Shirai, Michinori Matsumoto, Tomohiko Taniai, Masashi Tsunematsu, Mitsuru Yanagaki, Toru Ikegami. Incidental intrahepatic cholangiocarcinoma detected in the explant liver after living-donor liver transplantation for polycystic liver diseaseClinical Journal of Gastroenterology 2026;  doi: 10.1007/s12328-026-02343-y
3
Cristina Baciu, Bima J. Hasjim, Saba Maleki, Elisa Pasini, Meera Kennedybhai Patel, Maryam Shojaee, Amirhossein Azhie, Giovanna Saracino, Sumeet K. Asrani, Mamatha Bhat. Metabolomics Analysis Uncovers Distinct Profiles of Liver Post-Transplant Patients by Immunosuppression RegimenMetabolites 2025; 15(11): 700 doi: 10.3390/metabo15110700
Write to the Help Desk